SG11201907369TA - Anti-factor d antibodies and uses thereof - Google Patents
Anti-factor d antibodies and uses thereofInfo
- Publication number
- SG11201907369TA SG11201907369TA SG11201907369TA SG11201907369TA SG11201907369TA SG 11201907369T A SG11201907369T A SG 11201907369TA SG 11201907369T A SG11201907369T A SG 11201907369TA SG 11201907369T A SG11201907369T A SG 11201907369TA SG 11201907369T A SG11201907369T A SG 11201907369TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- philadelphia
- factor
- apt
- pct
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 235000014036 Castanea Nutrition 0.000 abstract 1
- 241001070941 Castanea Species 0.000 abstract 1
- 240000007049 Juglans regia Species 0.000 abstract 1
- 235000009496 Juglans regia Nutrition 0.000 abstract 1
- 230000004154 complement system Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000007062 hydrolysis Effects 0.000 abstract 1
- 238000006460 hydrolysis reaction Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 235000020234 walnut Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Environmental Sciences (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Biodiversity & Conservation Biology (AREA)
- Genetics & Genomics (AREA)
- Animal Husbandry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762457477P | 2017-02-10 | 2017-02-10 | |
| PCT/US2018/017537 WO2018148486A1 (en) | 2017-02-10 | 2018-02-09 | Anti-factor d antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907369TA true SG11201907369TA (en) | 2019-09-27 |
Family
ID=63107085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907369TA SG11201907369TA (en) | 2017-02-10 | 2018-02-09 | Anti-factor d antibodies and uses thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11434279B2 (he) |
| EP (1) | EP3580241A4 (he) |
| JP (2) | JP2020507581A (he) |
| KR (1) | KR20190129859A (he) |
| CN (1) | CN110461879B (he) |
| AU (1) | AU2018217720A1 (he) |
| BR (1) | BR112019016574A2 (he) |
| CA (1) | CA3053155A1 (he) |
| EA (1) | EA201991876A1 (he) |
| IL (1) | IL268601B2 (he) |
| MX (1) | MX2019009546A (he) |
| SG (1) | SG11201907369TA (he) |
| WO (1) | WO2018148486A1 (he) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL268601B2 (he) * | 2017-02-10 | 2024-07-01 | Univ Pennsylvania | נוגדנים נגד פקטור d ושימושים שלהם |
| IL269122B2 (he) * | 2017-03-06 | 2024-07-01 | Univ Pennsylvania | נוגדנים נגד c5 ושימושים שלהם |
| CN110240652B (zh) * | 2019-06-05 | 2022-09-06 | 百奥泰生物制药股份有限公司 | 抗补体d因子抗体及其应用 |
| WO2021202836A1 (en) * | 2020-04-01 | 2021-10-07 | The Trustees Of The University Of Pennsylvania | Factor b inhibitors and uses thereof |
| MX2022014275A (es) | 2020-05-12 | 2022-12-07 | Alexion Pharma Inc | Uso de inhibidores del factor d del complemento solos o junto con anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna. |
| CN114517184A (zh) * | 2020-10-30 | 2022-05-20 | 未来智人再生医学研究院(广州)有限公司 | 一种表达adipsin的多能干细胞或其衍生物及应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7112327B2 (en) | 1998-02-20 | 2006-09-26 | Tanox, Inc. | Inhibition of complement activation |
| SI2033659T1 (sl) * | 1998-02-20 | 2014-03-31 | Genentech, Inc. | Inhibitorji komplementne aktivacije |
| US7435804B2 (en) * | 2004-10-19 | 2008-10-14 | Phage Biotechnology, Inc. | Method for obtaining single chain antibodies to human interferon α2b |
| CN101948541B (zh) * | 2005-06-20 | 2014-08-06 | 健泰科生物技术公司 | 用于肿瘤诊断和治疗的组合物和方法 |
| WO2007056227A2 (en) | 2005-11-04 | 2007-05-18 | Genentech, Inc. | Use of complement pathway inhibitors to treat ocular diseases |
| PL2907827T3 (pl) | 2006-11-02 | 2019-03-29 | Genentech, Inc. | Humanizowane przeciwciała przeciw czynnikowi D i ich zastosowanie |
| AU2013200988B2 (en) | 2006-11-02 | 2015-09-17 | Genentech, Inc. | Humanized anti-Factor D antibodies |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| AR066660A1 (es) | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
| AU2016202258A1 (en) | 2007-05-23 | 2016-05-05 | Genentech, Inc. | Prevention and treatment of complement-associated eye conditions |
| AU2013213753A1 (en) * | 2007-05-23 | 2013-08-29 | Genentech, Inc. | Prevention and treatment of complement-associated eye conditions |
| CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
| WO2011140114A2 (en) | 2010-05-03 | 2011-11-10 | University Of Rochester | Anti-glucosaminidase passive immunization for staphylococcus aureus infections |
| US9243057B2 (en) * | 2010-08-31 | 2016-01-26 | The Regents Of The University Of California | Antibodies for botulinum neurotoxins |
| CN105175538B (zh) * | 2012-06-08 | 2019-01-08 | 厦门大学 | 抗hpv l1 蛋白的广谱单克隆抗体或其抗原结合片段及它们的用途 |
| CN105283196B (zh) | 2013-03-15 | 2018-10-12 | 贝丝以色列女执事医疗中心 | 用于产生和使用构象-特异性抗体的方法和组合物 |
| CA2944712A1 (en) * | 2014-05-01 | 2015-11-05 | Genentech, Inc. | Anti-factor d antibody variants and uses thereof |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| IL268601B2 (he) * | 2017-02-10 | 2024-07-01 | Univ Pennsylvania | נוגדנים נגד פקטור d ושימושים שלהם |
-
2018
- 2018-02-09 IL IL268601A patent/IL268601B2/he unknown
- 2018-02-09 AU AU2018217720A patent/AU2018217720A1/en active Pending
- 2018-02-09 EA EA201991876A patent/EA201991876A1/ru unknown
- 2018-02-09 BR BR112019016574-6A patent/BR112019016574A2/pt unknown
- 2018-02-09 JP JP2019543344A patent/JP2020507581A/ja not_active Ceased
- 2018-02-09 KR KR1020197026590A patent/KR20190129859A/ko active IP Right Grant
- 2018-02-09 CN CN201880020860.8A patent/CN110461879B/zh active Active
- 2018-02-09 US US16/484,962 patent/US11434279B2/en active Active
- 2018-02-09 SG SG11201907369TA patent/SG11201907369TA/en unknown
- 2018-02-09 WO PCT/US2018/017537 patent/WO2018148486A1/en unknown
- 2018-02-09 CA CA3053155A patent/CA3053155A1/en active Pending
- 2018-02-09 MX MX2019009546A patent/MX2019009546A/es unknown
- 2018-02-09 EP EP18751478.1A patent/EP3580241A4/en active Pending
-
2022
- 2022-07-26 US US17/814,980 patent/US20230032737A1/en active Pending
- 2022-12-23 JP JP2022206631A patent/JP2023040069A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN110461879A (zh) | 2019-11-15 |
| IL268601A (he) | 2019-09-26 |
| WO2018148486A8 (en) | 2019-09-19 |
| IL268601B1 (he) | 2024-03-01 |
| US20190359699A1 (en) | 2019-11-28 |
| EP3580241A1 (en) | 2019-12-18 |
| JP2020507581A (ja) | 2020-03-12 |
| IL268601B2 (he) | 2024-07-01 |
| RU2019128203A3 (he) | 2021-11-12 |
| US11434279B2 (en) | 2022-09-06 |
| AU2018217720A1 (en) | 2019-09-05 |
| EA201991876A1 (ru) | 2020-03-13 |
| JP2023040069A (ja) | 2023-03-22 |
| BR112019016574A2 (pt) | 2020-03-31 |
| US20230032737A1 (en) | 2023-02-02 |
| WO2018148486A1 (en) | 2018-08-16 |
| RU2019128203A (ru) | 2021-03-10 |
| CA3053155A1 (en) | 2018-08-16 |
| CN110461879B (zh) | 2024-03-29 |
| KR20190129859A (ko) | 2019-11-20 |
| EP3580241A4 (en) | 2021-01-06 |
| MX2019009546A (es) | 2019-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908238SA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201907369TA (en) | Anti-factor d antibodies and uses thereof | |
| SG11201907580SA (en) | Combination therapies for treatment of bcma-related cancers and autoimmune disorders | |
| SG11201808724SA (en) | Anti-tim-3 antibodies and compositions | |
| SG11201811740WA (en) | Systems and methods for identifying risky driving behavior | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
| SG11201906200WA (en) | Nucleic acid-polypeptide compositions and methods of inducing exon skipping | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11202000105QA (en) | Anti-cd166 antibodies and uses thereof | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
| SG11201908744PA (en) | Anti-c5a antibodies and uses thereof | |
| SG11201900201YA (en) | Methods for quantitating individual antibodies from a mixture | |
| SG11201805422WA (en) | Multivalent and multispecific ox40-binding fusion proteins | |
| SG11201807421TA (en) | The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| SG11201901347UA (en) | Compositions and methods for cancer immunotherapy |